Cardiff Oncology (NASDAQ:CRDF) CEO Mani Mohindru Buys 24,703 Shares of Stock

Cardiff Oncology, Inc. (NASDAQ:CRDF) CEO Mani Mohindru acquired 24,703 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was purchased at an average cost of $1.21 per share, with a total value of $29,890.63. Following the completion of the purchase, the chief executive officer directly owned 24,703 shares in the company, valued at $29,890.63. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Cardiff Oncology Trading Up 7.4%

Shares of CRDF opened at $1.30 on Tuesday. Cardiff Oncology, Inc. has a 12-month low of $1.16 and a 12-month high of $4.55. The stock has a market cap of $88.88 million, a P/E ratio of -1.94 and a beta of 1.36. The company has a 50-day moving average of $1.62 and a two-hundred day moving average of $1.97.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Cardiff Oncology had a negative return on equity of 95.51% and a negative net margin of 8,527.43%.The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.09 million. As a group, analysts forecast that Cardiff Oncology, Inc. will post -0.66 EPS for the current fiscal year.

Hedge Funds Weigh In On Cardiff Oncology

Several hedge funds and other institutional investors have recently modified their holdings of CRDF. Bank of America Corp DE lifted its position in Cardiff Oncology by 23.9% during the first quarter. Bank of America Corp DE now owns 51,119 shares of the company’s stock valued at $83,000 after buying an additional 9,855 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Cardiff Oncology in the first quarter worth $164,000. Sei Investments Co. purchased a new position in shares of Cardiff Oncology in the 1st quarter valued at $89,000. Virtu Financial LLC acquired a new position in shares of Cardiff Oncology during the 4th quarter valued at $108,000. Finally, XTX Topco Ltd boosted its position in Cardiff Oncology by 40.5% during the 4th quarter. XTX Topco Ltd now owns 219,357 shares of the company’s stock worth $616,000 after purchasing an additional 63,196 shares during the period. 16.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CRDF shares. TD Cowen lowered shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a report on Monday, June 1st. Piper Sandler cut their price objective on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Craig Hallum downgraded shares of Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research note on Wednesday, June 3rd. Wall Street Zen lowered shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, HC Wainwright cut shares of Cardiff Oncology from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $8.75.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.